首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到20条相似文献,搜索用时 203 毫秒
1.
目的了解硫氮酮对慢性阻塞性肺病(COPD)所致肺动脉高压的治疗效果。方法对11例慢性肺心病急性发作期患者给予静脉注射硫氮酮治疗并作动态血流动力学及氧动力学监测。结果发现静脉注射硫氮酮可迅速降低肺动脉压、肺血管阻力指数和右心房平均压(分别降低062~127kPa、140kPa·s-1·L-1和027~040kPa,P均<005);心率明显下降(下降25~30次/分,P<005),同时心脏指数、每搏射血指数均上升(分别增加03~06L·min-1·m-2和5~9ml·beat-1·m-2,P均<005);用药后外周动脉血压、氧动力学指标及肺血分流率均无显著变化。结论静脉注射硫氮酮对慢性肺心病急性发作期患者有良好的血流动力学效应,对合并室上性快速心律失常的病例有积极的应用指征  相似文献   

2.
目的观察一氧化氮底物左旋精氨酸(L一arg)延长吸入一氧化氮(NO)选择性降低肺动脉高压过程中的作用。方法8只猪麻醉后制成急性缺氧性肺动脉高压模型,在 Swan-Ganz导管和动脉导管监测下吸入 NO(12— 15ppm)的过程中静脉注入 L- arg(共 10g),观察停用 NO后体循环和肺循环血流动力学的变化情况。结果单纯吸入 NO能选择性降低急性缺氧性肺动脉高压,肺动脉压力从 4 2± 0 4kPa降至 2. 5± 0 .5kPa(1kPa= 7.5mmHg, P< 0.01),肺血管阻力从 56±25kPa·s·L-1降至31±13kPa·s·L-1(P<0.01),但持续时间短;NO吸入加静脉注射L-arg没有使肺动脉压进一步下降,但能显著延长吸入NO对肺动脉压的降压时间(20倍),对体循环血压则无影响。结论提供内源性NO的底物L-arg能延长NO的降压作用,提示急性缺氧时NO的生成可能有相对不足。  相似文献   

3.
目的:探讨静脉滴注硝酸甘油(nitroglycerin, NTG)对室间隔缺损合并充血性心力衰竭婴幼儿血流动力学影响。方法:15 例室间隔缺损合并充血性心力衰竭婴幼儿,在连续监测心率和血压的情况下,静脉滴注NTG0 .4~0 .8 μg·kg- 1·min -1 ,利用超声心动图在用药前、用药后1 h、6 h 分别测定左心室射血分数(ejectionfraction,EF) 、短轴缩短率(fractionalshortening,FS)、肺动脉平均压(pulmonary artery mean pressure,PAMP) 、肺毛细血管楔压(pulmonarycapillary wedge pressure,PCWP) 和左心室壁应力(left ventricular wallstress,LVWS) 等。结果:PCWP用药前(2.8 ±0 .4) kPa,用药后1 h 降至(1.7 ±0 .4) kPa,6 h 降至(1.6±0.4) kPa( P< 0 .05) ;LVWSⅠ用药前(4-32±0-56) N/cm2 ,用药后1 h 降至(3-65 ±0-59) N/cm2 ,6 h 降至(3-87 ±0-60) N/cm2( P< 0.05) ;LVW  相似文献   

4.
本文观察15只正常狗麻醉后于自主呼吸、机械正常通气、机械过度通气及纠正呼吸性碱中毒后4个阶段的血流动力学变化,发现过度通气后PAP及CO显著下降,分别为2.551±0.650/2.765±0.791kPa,P<0.01和2.131±0.633/2.329±0.780L/min(P<0.05),二者显著相关(r=0.6192,P<0.02).气道平均压显著增高,表明(1)呼碱可直接影响PAP及CO;(2)HV使胸内压升高;(3)呼碱时血钙降低,心肌收缩力下降;(4)后负荷增加.建议临床使用HV治疗肺动脉高压时应防止严重呼碱及胸内压过度增高,并加强血流动力学的监侧。  相似文献   

5.
对15例慢性阻塞性肺病(COPD)患者应用右心漂浮导管检测技术,观察了川芎嗪与尼群地平配伍对血流动力学的影响。同时,用放射免疫法测定了治疗前后肺动脉混合静脉血浆内皮素-1(ET-1)、血栓素B2(TXB2)、6-酮-前列腺素F1α(6-Keto-PGF1α)浓度。结果发现:用药即刻和15、30、60min时肺动脉平均压(mPAP)分别下降了1.4%、17.0%、20.0%、18.0%;肺循环阻力(  相似文献   

6.
分别对4例及6例肾移植患者单用环孢素与合用硫氮Zhuo酮后CsA的药物动力学变化进行研究。并观察了其中9例患者血药浓度达峰时血浆超氧化物歧化酶活性的变化,结果表明:肾移植患者CsA药动学参数个体差异大,合用硫氮Zhuo酮后,CsA的β和T1/2α显著性降低,T1/2β显著性升高,峰浓度有一定升高,其它参数无显著改变(P〉0.05),合用硫氮Zhuo酮后血浆SOD活性有一定增大。  相似文献   

7.
老年慢性阻塞性肺病患者的茶碱药代动力学及临床应用   总被引:2,自引:0,他引:2  
40例慢性阻塞性肺病患者进行氨茶碱对代动力学测定结果显示,慢性喘息性支气管炎消除速率常数(K)0.0934±0.014h^-1消除半衰期(T1/2)7.6±1.27,肺心病伴肺部感染或呼吸衰竭K0.065±0.02h^-1,T1/211.99±3.87h,肺心病伴心,肝功能异常者K0.038±0.016h^-1,T1/221.48±9.5h,比较3种给药方法的血药浓度,并探讨适全我国老年COPD患  相似文献   

8.
11例慢性阻塞性肺病合并肺动脉高压分别应用乌拉地尔和开搏通治疗。血流动力学检查结果表明:乌拉地尔降低肺动脉平均压0.72kPa,肺血管阻力28.8%,体循环和21.6%。平均提高心脏指数15.0ml.s^-1/m^2,血氧运输量29%。  相似文献   

9.
王立峰  云华亭 《中原医刊》1999,26(10):10-12
报告21例经皮球囊二次瓣成形术(PBMV)全部成功,二尖瓣口面积自术前1.11±0.12增至术后2.63±0.32cm^2(P〈0.001)左心房平均压自3.15±1.28降至1.21±0.56kPa(P〈0.001),二尖压力阶差自2.28±0.90降为0.72±0.63kPa(P〈0.001),肺动脉平均压自3.97±1.35降为2.19±0.71kPa(P〈0.001),随访2周至12个月显  相似文献   

10.
L精氨酸对大鼠低氧性肺动脉高压的防治作用   总被引:1,自引:0,他引:1  
观察L-精氨酸对大鼠常压低氧性肺动脉高压的预防和治疗作用。结果表明,L-精氨酸(200mg/kg·d)可明显预防低氧所致的肺动脉高压和右心室肥厚,L-精氨酸预防组平均肺动脉压(mPAP)(2.61±0.09kPa)明显低于低氧处理组(3.58±0.06kPa),两组间差异有显著性(P〈0.05);右心室/(左心室+室间隔)重量比值(0.26±0.01)明显低于低氧组(0.34±0.01),两组间差  相似文献   

11.
C Wang 《中华医学杂志》1992,72(9):553-5, 574
Amrinone was given intravenously combined with the routine treatment to 10 patients with late chronic cor pulmonale in exacerbation stage. The initial loading dose was 1.5-2 mg/kg followed by the maintenance dose of 15 micrograms/kg. min for 6 hours. Hemodynamic and blood gas monitoring showed that pulmonary artery pressure, pulmonary vascular resistance index, right atrial pressure and pulmonary capillary wedge pressure decreased significantly and maintained the level markedly below baseline after amrinone administration (the extents decreased were 0.53-1.1 kPa, 80-140 dyn.s.m2.cm-5, 0.27-0.40 kPa and 0.40-0.67 kPa respectively. P < 0.05 for each parameter) and that cardiac index and stroke volume index increased identically (the extents increased were 0.3-0.6 L/min.m2 and 2-4 ml/beat.m2 respectively, P < 0.05 for each parameter). There were no significant changes in systemic artery pressure, arterial blood gas analysis and blood platelet count after amrinone administration. We suggest that amrinone may be effective in the treatment of cardio-pulmonary decompensated chronic cor pulmonale.  相似文献   

12.
Background  Pulmonary angiography is widely performed in pulmonary hypertension patients, but its immediate effects on right heart hemodynamics and safety are not well known. The objective of this study was to investigate the right heart hemodynamic effects and safety of pulmonary angiography in Chinese patients with pulmonary hypertension.
Methods  Between January 2008 and June 2009, pulmonary hypertension patients undergoing pulmonary angiography were consecutively enrolled. Pulmonary angiography was performed during breath-holding after deep breathing. The baseline clinical data, hemodynamic measurements before and after pulmonary angiography and complications occurring within 48 hours after angiography were recorded.
Results  Ninety-five patients were included. All received non-ionic contrast medium with a volume of (75.7±29.8) ml. Angiography reduced heart rate in patients with baseline mean pulmonary arterial pressure ≥ 60 mmHg (change of heart rate: (3.1±7.0) beats/min, P=0.005), increased mean right atrial pressure, diastolic and end-diastolic right ventricular pressure in patients with baseline mean pulmonary arterial pressure <60 mmHg (all P <0.05). Patients with decreased mean pulmonary arterial pressure (change of mean pulmonary arterial pressure ≤ –10 mmHg) had the highest total pulmonary resistance (P=0.009 vs. no change in mean pulmonary arterial pressure (change of mean pulmonary arterial pressure, –10 mmHg to 10 mmHg); P=0.03 vs. increased mean pulmonary arterial pressure (change of mean pulmonary arterial pressure ≥ 10 mmHg)) and the lowest cardiac output (P=0.018 vs. no change in mean pulmonary arterial pressure; P=0.013 vs. increased mean pulmonary arterial pressure). There were 7 complications (7%), with 6 related to catheter and only 1 directly related to angiography. All complications were mild and no death occurred.
Conclusion  Pulmonary angiography has minimal effect on right heart hemodynamics and is safe in pulmonary hypertension patients.
  相似文献   

13.
S Chen 《中华医学杂志》1991,71(3):150-2, 12
The role of angiotensin system in the development of hypoxic pulmonary hypertension, in nine pigs (50 +/- 8 kg) were studied. A Swan-Ganz Catheter and an arterial catheter were inserted into the pulmonary artery and aorta, pulmonary arterial pressure (PAP), pulmonary capillary wedge pressure (PCWP), Cardiac output (CO) and arterial blood gases were monitored before and after hypoxia and captopril injection (7.3 mg/kg.iv). Plasma renin activity (PRA) and angiotensin II (AT-II) were measured by RIA. Angiotensin converting enzyme (ACE) was measured by fluorometry. Results showed that during hypoxemia (PaO2 6.3 +/- 0.2 kPa, PaCO2 5.4 +/- 0.2 kPa), PAP increased from 2.43 +/- 0.17 to 3.76 +/- 0.2 kPa, (P less than 0.05) and right ventricle stroke work index (BVSWI) from 55.7 +/- 7.2 to 91.3 +/- 9.3 mJ/m2 (P less than 0.05). PRA increased from 0.56 +/- 0.19 to 1.28 +/- 6.30 mol. L-1/h (P less than 0.02) and AT-II from 62.4 +/- 17.4 to 133.3 +/- 31.8 ng/L (P less than 0.01); but ACE decreased from 77.6 +/- 5.6 to 58.4 +/- 4.2 mumol.min-1/L (P less than 0.02). After Captopril injection ACE was reduced to 26.7 +/- 3.4 mumol.min-1/L (P less than 0.001) and AT-II dropped to 61.9 +/- 15.5 ng/L (P less than 0.01), as compared with those during hypoxemia. There was significant correlation between PAP and PRA (r = 0.5643 P less than 0.01). We surmise that angiotensin system may play a part in acute hypoxia-induced pulmonary hypertension, and captopril Inhibits AT-II, leading to the drop of pulmonary arterial pressure.  相似文献   

14.
目的探讨纳络酮对慢性阻塞性肺疾病(COPD)急性发作期合作并肺性脑病(PEP)的临床疗效。方法选择我院自2001年1月~2004年12月76例COPD急性发作期合并肺性脑病患者,分成两组应用纳络酮组为试验组(A组),未用纳络酮组为对照组(B组),每组各38例。观察用药前后的意识状态,呼吸、血压、心率、动脉血气分析的变化。结果A组用药后24小时内意识障碍消失30例(78.9%)、48小时内36例(89.5%);而B组24小时内有13例意识障碍消失(34.2%)、48小时内22例(50.0%)。二者相比有显著性差异。血压无显著意义变化。A组用药后呼吸、心率有显著意义的下降(P<0.05),呼吸频率下降8~15次/分,心率下降20~40次/分。PaCO2与用药前相比,有显著意义的下降(P<0.05),下降2.8~5.6kPa。PaO2与用药前相比均有显著意义的升高(P<0.05),升高2.1~3.6kPa。A组RR、HR、PaCO2明显低于B组(P<0.05),PaO2明显高于B组(P<0.05)。结论纳络酮对COPD急性发作期合并的肺性脑病,具有一定的治疗作用。  相似文献   

15.
L-精氨酸干预低氧性肺血管结构重构机制的研究   总被引:20,自引:0,他引:20  
探讨L-精氨酸干预低氧性肺血管结构重构的机制。方法将18只Wistar大鼠采用区组随机法分为对照组、低氧组和低氧+L-Arg组。以右心导管法测定肺动脉压力,并对大示本进行显微结构观测和超微结构观察,同时分光光度法间接测定血浆一氧化氮(NO)含量,并对肺组织以内皮素-1(ET-1)cRNA探针进行原位杂交,研究肺动脉内皮细胞ET-1mRNA的表达。结果低氧组大鼠肺动脉平均压(mPAP)为2.71KP  相似文献   

16.
Theophylineisoneofthemostwidelyuseddrugsintreatingchronicobstructivepulmonarydisease(COPD).However,thetraditionaltheorythatth...  相似文献   

17.
祁玉凤  邵强  沈兵 《中华全科医学》2021,19(9):1504-1506
  目的  探讨慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD,以下简称慢阻肺)患者肺功能、血气分析、肺动脉收缩压与慢性阻塞性肺疾病评估测试(COPD assessment test,CAT)评分的关系。   方法  将六安市人民医院呼吸内科2019年9—12月收治的106例COPD患者按照CAT评分法进行疾病状态评定,分为病情轻微组(11例)、中等组(28例)、严重组(41例)、非常严重组(26例),比较不同疾病状态下COPD患者的肺功能,包括第1秒用力呼气容积(forced expiratory volume in one second,FEV1)、一秒率[FEV1/用力肺活量(forced vital capacity,FVC)]、呼气流量峰值(peak expiratory flow,PEF), 血气分析[氧分压(PaO2)、二氧化碳分压(PaCO2)], 肺动脉收缩压(systolic pulmonary artery pressure, sPAP)的差异,探讨各指标与CAT评分的相关性。   结果  CAT评分越低的患者,肺功能各项指标(FEV1、FEV1/FVC、PEF)越高(均P < 0.05);患者CAT评分越低,PaO2越高,PaCO2越低(均P < 0.05),sPAP也越低(P < 0.05);尤其在CAT评分>20分的患者,上述差异尤其明显。Pearson相关分析显示,FEV1、FEV1/FVC、PEF、PaO2与CAT评分呈负相关,PaCO2、sPAP与CAT评分呈正相关。   结论  COPD患者的CAT评分与肺功能、肺动脉收缩压、血气分析指标之间存在相关性,说明CAT评分可以有效预测COPD患者的换气和通气功能障碍,评价患者的肺功能情况。   相似文献   

18.
目的研究慢性阻塞性肺疾病(COPD)患者睡眠时低氧血症发生的可预测因素。方法分析和比较28例COPD患者与20例正常对照者的肺功能、白天动脉血气及夜间血氧水平。结果 COPD患者夜间平均血氧饱和度(MSaO2)、夜间最低血氧饱和度(LSaO2)较正常对照组明显下降(P<0.05)。COPD患者睡眠时动脉血氧饱和度(SaO2)<90%的时间占睡眠时间百分比(T90)亦显著高于正常对照(P<0.01)。日间SaO2、一秒钟用力呼气容积(FEV1)绝对值与夜间MSaO2相关(r值依次0.704、0.435,P<0.01)。建立了夜间血氧水平的预测公式:MSaO2(%)=0.536×日间SaO2(%)+2.35×FEV1绝对值(L)+38.805。日间SaO2、FEV1绝对值与夜间睡眠时血氧饱和度分布有关。结论 COPD患者睡眠时血氧饱和度较正常人出现明显下降,此时的血氧水平和分布可以通过日间SaO2、FEV1绝对值进行预测。  相似文献   

19.
目的 评价雾化吸入米力农对慢性阻塞性肺疾病(COPD)合并肺动脉高压(PH)患者手术中心功能和肺动脉压改善的临床效果.方法 选择2015年6月至2016年6月重庆市急救中心确诊为COPD合并PH的手术患者44例,其中胸部手术23例,腹部手术13例,下肢骨折手术8例.患者分为对照组与治疗组,各22例.对照组接受常规综合治疗;治疗组除接受常规综合治疗外,在全身麻醉前雾化吸入米力农.两组均右颈内静脉置入漂浮导管检测临床指标:心输出量(CO)、肺动脉收缩压(PASP)、肺动脉平均压(PAMP)、肺动脉毛细血管楔坎压(PCWP).结果 治疗组治疗后较治疗前CO明显增高(P<0.05);PASP、PAMP、PCW明显降低(P<0.05).对照组治疗前后CO、PASP、PAMP、PCWP无明显改善,比较差异无统计学意义(P>0.05).结论 COPD合并PH患者在手术前雾化吸入米力农,可以有效改善患者的心肺功能.  相似文献   

20.
目的探讨慢性阻塞性肺疾病患者急性加重期(AECOPD)细胞因子的变化及沙美特罗替卡松的临床疗效。方法选择210例COPD患者做为研究对象,其中AECOPD患者120例,稳定期COPD患者90例。将120例AE-COPD患者随机分入对照组与观察组,每组各60例。对照组患者给予硫酸沙丁胺醇雾化吸入,观察组患者接受沙美特罗替卡松吸入治疗。结果 AECOPD患者血清细胞因子超敏C-反应蛋白(hs-CRP)、白介素8(IL-8)、肿瘤坏死因子-α(TNF-α)水平显著高于稳定期COPD患者(P〈0.01);肺功能第1秒用力呼气容积(FEV1),FEV1与用力肺活量比值(FEV1/FVC)显著低于稳定期COPD患者(P〈0.01);治疗后观察组与对照组患者hs-CRP、IL-8、TNF-α均显著下降(P〈0.05),但观察组患者细胞因子水平明显低于对照组(P〈0.05),肺功能FEV1、FEV1/FVC值优于对照组(P〈0.05)。结论AECOPD血清细胞因子水平显著增高,沙美特罗替卡松可显著降低细胞因子水平,改善肺功能。  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号